Samumed Stock
R&D for tissue-level regeneration
About Samumed Stock
Samumed is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. Founded in San Diego, California in 2008, Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.
Investors
Funding History
| September 2013 | $220M |
|---|---|
| August 2018 | $438M |
Management
Founder & Chief Executive Officer
Osman Kibar
Chief Medical Officer
Yusuf Yazici
Chief Financial Officer
Cevdet Samikoglu
Chief Legal Officer
Arman Oruc
Chief Business Officer
Erich Horsley
Chief Operating Officer
Philippe Marchand
Chief Information Officer
Blake Mobley
Press
Intrado - Oct, 2 2019
Intrado - Jul, 18 2019
Intrado - May, 2 2019
Globe Newswire - Feb, 28 2019
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Samumed or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
